For decades, rare disease patients have lived within a paradox. They were too few to study—and therefore too few to treat. Traditional drug approval systems, built on large-scale clinical trials, unintentionally excluded them. Without enough patients, trials could not proceed. Without trials, treatments could not be approved. The result was a systemic dead end—what clinicians … Continue reading AI Breaks the Clinical Trial Bottleneck for Rare Disease Patients